# Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

> **NCT03610581** · PHASE1,PHASE2 · TERMINATED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 9 (actual)

## Conditions studied

- Human Papillomavirus Infections

## Interventions

- **BIOLOGICAL:** Ad26.HPV16
- **BIOLOGICAL:** Ad26.HPV18
- **BIOLOGICAL:** MVA.HPV16/18
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03610581
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-27
- **Primary completion:** 2020-10-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610581, "Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03610581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*